140 related articles for article (PubMed ID: 16472937)
1. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
Fujita T; Teh BS; Timme TL; Mai WY; Satoh T; Kusaka N; Naruishi K; Fattah EA; Aguilar-Cordova E; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):84-90. PubMed ID: 16472937
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
3. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
4. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
[TBL] [Abstract][Full Text] [Related]
5. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
6. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
7. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
9. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
[TBL] [Abstract][Full Text] [Related]
12. Standard treatments induce antigen-specific immune responses in prostate cancer.
Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
[TBL] [Abstract][Full Text] [Related]
13. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
D'Amico AV; Renshaw AA; Loffredo B; Chen MH
Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
15. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
17. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
19. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
[TBL] [Abstract][Full Text] [Related]
20. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.
Yassa M; Fortin B; Fortin MA; Lambert C; Van Nguyen T; Bahary JP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):58-63. PubMed ID: 18406883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]